Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Dongcheng District, Beijing, China.
Phytother Res. 2023 May;37(5):1864-1882. doi: 10.1002/ptr.7703. Epub 2023 Feb 5.
Shenlian (SL) extract has been proven to be effective in the prevention and treatment of atherosclerosis and myocardial ischemia. However, the function and molecular mechanisms of SL on coronary artery no-reflow have not been fully elucidated. This study was designed to investigate the contribution of SL extract in repressing excessive mitochondrial autophagy to protect the mitochondrial function and prevent coronary artery no-reflow. The improvement of SL on coronary artery no-reflow was observed in vivo experiments and the molecular mechanisms were further explored through vitro experiments. First, a coronary artery no-reflow rat model was built by ligating the left anterior descending coronary artery for 2 hr of ischemia, followed by 24 hr of reperfusion. Thioflavin S (6%, 1 ml/kg) was injected into the inferior vena cava to mark the no-reflow area. Transmission electron microscopy was performed to observe the cellular structure, mitochondrial structure, and mitochondrial autophagy of the endothelial cells. Immunofluorescence was used to observe the microvascular barrier function and microvascular inflammation. Cardiac microvascular endothelial cells (CMECs) were isolated from rats. The CMECs were deprived of oxygen-glucose deprivation (OGD) for 2 hr and reoxygenated for 4 hr to mimic the Myocardial ischemia-reperfusion (MI/R) injury-induced coronary artery no-reflow in vitro. Mitochondrial membrane potential was assessed using JC-1 dye. Intracellular adenosine triphosphate (ATP) levels were determined using an ATP assay kit. The cell total reactive oxygen species (ROS) levels and cell apoptosis rate were analyzed by flow cytometry. Colocalization of mitochondria and lysosomes indirectly indicated mitophagy. The representative ultrastructural morphologies of the autophagosomes and autolysosomes were also observed under transmission electron microscopy. The mitochondrial autophagy-related proteins (LC3II/I, P62, PINK, and Parkin) were analyzed using Western blot analysis. In vivo, results showed that, compared with the model group, SL could reduce the no-reflow area from 37.04 ± 9.67% to 18.31 ± 4.01% (1.08 g·kg SL), 13.79 ± 4.77% (2.16 g·kg SL), and 12.67 ± 2.47% (4.32 g·kg SL). The extract also significantly increased the left ventricular ejection fraction (EF) and left ventricular fractional shortening (FS) (p < 0.05 or p < 0.01). The fluorescence intensities of VE-cadherin, which is a junctional protein that preserves the microvascular barrier function, decreased to ~74.05% of the baseline levels in the no-reflow rats and increased to 89.87%(1.08 g·kg SL), 82.23% (2.16 g·kg SL), and 89.69% (4.32 g·kg SL) of the baseline levels by SL treatment. SL administration repressed the neutrophil migration into the myocardium. The oxygen-glucose deprivation/reoxygenation (OGD/R) model was induced in vitro to mimic microvascular ischemia-reperfusion injury. The impaired mitochondrial function after OGD/R injury led to decreased ATP production, calcium overload, the excessive opening of the Mitochondrial Permeability Transition Pore, decreased mitochondrial membrane potential, and reduced ROS scavenging ability (p < 0.05 or p < 0.01). The normal autophagosomes (double-membrane vacuoles with autophagic content) in the sham group were rarely found. The large morphology and autophagosomes were frequently observed in the model group. By contrast, SL inhibited the excessive activation of mitochondrial autophagy. The mitochondrial autophagy regulated by the PINK/Parkin pathway was excessively activated. However, administration of SL prevented the activation of the PINK/Parkin pathway and inhibited excessive mitochondrial autophagy to regulate mitochondrial dysfunction. Results also demonstrated that mitochondrial dysfunction stimulated endothelial cell barrier dysfunction, but Evans blue transmission was significantly decreased and transmembrane resistance was increased significantly by SL treatment (p < 0.05 or p < 0.01). Carbonylcyanide-3-chlorophenylhydrazone (CCCP) could activate the PINK/Parkin pathway. CCCP reversed the regulation of SL on mitochondrial autophagy and mitochondrial function. SL could alleviate coronary artery no-reflow by protecting the microvasculature by regulating mitochondrial function. The underlying mechanism was related to decreased mitochondrial autophagy by the PINK/Parkin pathway.
神连(SL)提取物已被证明可有效预防和治疗动脉粥样硬化和心肌缺血。然而,SL 对冠状动脉无复流的作用及其分子机制尚未完全阐明。本研究旨在探讨 SL 提取物抑制过度线粒体自噬以保护线粒体功能和防止冠状动脉无复流的作用。通过体内实验观察到 SL 对冠状动脉无复流的改善,并通过体外实验进一步探讨其分子机制。首先,通过结扎左前降支 2 小时缺血,然后再灌注 24 小时,建立冠状动脉无复流大鼠模型。将硫代黄素 S(6%,1ml/kg)注入下腔静脉标记无复流区。通过透射电镜观察内皮细胞的细胞结构、线粒体结构和线粒体自噬。免疫荧光法观察微血管屏障功能和微血管炎症。从大鼠中分离心脏微血管内皮细胞(CMECs)。将 CMECs 进行缺氧-葡萄糖剥夺(OGD)2 小时,然后再氧合 4 小时,以模拟体外心肌缺血再灌注(MI/R)损伤引起的冠状动脉无复流。使用 JC-1 染料评估线粒体膜电位。使用 ATP 测定试剂盒测定细胞内三磷酸腺苷(ATP)水平。通过流式细胞术分析细胞总活性氧(ROS)水平和细胞凋亡率。线粒体和溶酶体的共定位间接表明自噬。还通过透射电子显微镜观察自噬体和自噬溶酶体的代表性超微结构形态。使用 Western blot 分析检测线粒体自噬相关蛋白(LC3II/I、P62、PINK 和 Parkin)。在体内,结果表明,与模型组相比,SL 可使无复流面积从 37.04±9.67%减少至 18.31±4.01%(1.08g·kg SL)、13.79±4.77%(2.16g·kg SL)和 12.67±2.47%(4.32g·kg SL)。该提取物还显著增加左心室射血分数(EF)和左心室缩短分数(FS)(p<0.05 或 p<0.01)。无复流大鼠的 VE-钙黏蛋白(一种保持微血管屏障功能的连接蛋白)荧光强度降至基线水平的约 74.05%,而 SL 处理可增加至 89.87%(1.08g·kg SL)、82.23%(2.16g·kg SL)和 89.69%(4.32g·kg SL)。SL 给药抑制中性粒细胞向心肌迁移。通过体外建立氧-葡萄糖剥夺/再氧合(OGD/R)模型,模拟微血管缺血再灌注损伤。OGD/R 损伤后线粒体功能受损导致 ATP 生成减少、钙超载、线粒体通透性转换孔过度开放、线粒体膜电位降低和 ROS 清除能力降低(p<0.05 或 p<0.01)。在假手术组中很少发现正常的自噬体(具有自噬内容物的双层膜空泡)。在模型组中经常观察到大形态和自噬体。相比之下,SL 抑制了过度的线粒体自噬激活。PINK/Parkin 通路调节的线粒体自噬过度激活。然而,SL 给药可阻止 PINK/Parkin 通路的激活并抑制过度的线粒体自噬以调节线粒体功能障碍。结果还表明,线粒体功能障碍刺激内皮细胞屏障功能障碍,但 SL 处理可显著降低 Evans 蓝的传输并显著增加跨膜电阻(p<0.05 或 p<0.01)。羰基氰化物-3-氯苯腙(CCCP)可激活 PINK/Parkin 通路。CCCP 逆转了 SL 对线粒体自噬和线粒体功能的调节。SL 通过调节线粒体功能来减轻冠状动脉无复流,从而保护微血管。其潜在机制与通过 PINK/Parkin 通路减少线粒体自噬有关。